MRC Clinical Research Professorship
Lead Research Organisation:
University of Southampton
Department Name: Medicine
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
- University of Southampton, United Kingdom (Fellow, Lead Research Organisation)
- University of Groningen (Collaboration)
- Hebrew University of Jerusalem (Collaboration)
- Manchester University NHS Foundation Trust, Manchester (Collaboration)
- Ajou University (Collaboration)
- University of East Anglia, United Kingdom (Collaboration)
- University of Cincinnati (Collaboration)
- University of Melbourne, Australia (Collaboration)
- University of Nottingham (Collaboration)
- University of Manchester, Manchester, United Kingdom (Collaboration)
- Wake Forest University, United States (Collaboration)
People |
ORCID iD |
| Stephen Holgate (Principal Investigator / Fellow) |
Publications
An SS
(2016)
An inflammation-independent contraction mechanophenotype of airway smooth muscle in asthma.
in The Journal of allergy and clinical immunology
Andrews AL
(2006)
IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets.
in Journal of immunology (Baltimore, Md. : 1950)
Andrews AL
(2006)
IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts.
in The Journal of allergy and clinical immunology
Babu SK
(2011)
Tumor necrosis factor alpha (TNF-a) autoregulates its expression and induces adhesion molecule expression in asthma.
in Clinical immunology (Orlando, Fla.)
Bachert C
(2020)
Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge
in European Respiratory Journal
Belvisi M
(2016)
The ever-expanding ERS fellowship programmes: achievements over the past 3 years
in European Respiratory Journal
Bjornsdottir US
(2011)
Pathways activated during human asthma exacerbation as revealed by gene expression patterns in blood.
in PloS one
Bousquet J
(2010)
Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma.
in The Journal of allergy and clinical immunology
Boxall C
(2006)
The contribution of transforming growth factor-beta and epidermal growth factor signalling to airway remodelling in chronic asthma.
in The European respiratory journal
Bradding P
(2006)
The role of the mast cell in the pathophysiology of asthma.
in The Journal of allergy and clinical immunology
| Description | Advice to the Public on Acute Air Pollution Episodes |
| Geographic Reach | National |
| Policy Influence Type | Citation in other policy documents |
| Impact | We used new research to redefine the threholds for medical advice on air pollution episodes in the UK. This was a COMEAP Subgroup that I chaired. |
| URL | https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/304633/COMEAP_review_of_th... |
| Description | Advisory Committee for Hazardous Substances (ACHS, Defra) |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a advisory committee |
| Impact | Advice to Government and the public on chemical regulation. |
| URL | https://www.gov.uk/government/groups/hazardous-substances-advisory-committee |
| Description | Advisory Committeeon Novel Foods and Processes |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Impact | Protection of the public through regulation and labelling. I completed my term in 2014 |
| URL | http://acnfp.food.gov.uk/ |
| Description | Appointed Chair Main Panel A (Medical, Health and Life Sciences) for Research Excellence Framework 2014 |
| Geographic Reach | National |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Impact | Oversaw 6 SubPanels to assess research quality of outputs, environment and impacts across 156 UK Universities. Reported Dec 2014 |
| URL | http://www.ref.ac.uk/ |
| Description | Board Chair NC3Rs |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Impact | NC3Rs Board Chair appointed by interview. Help in setting the straegic diection of NC3Rs and implement the different grants panels and forms of funding (e.g.CrackIt) |
| URL | https://www.nc3rs.org.uk/about-us/board |
| Description | Board of Management of the World Allergy Organisation. |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a advisory committee |
| Impact | Many outputs, but mostly organising and advising on international activities in Allergy (including its recognition as a public healthy problem). After being a Board member for 4 years I was selected to be Treasurer that I did for a further 2 years before demitting. |
| URL | http://www.worldallergy.org/ |
| Description | Chair Scientific Committee, European Respiratory Society |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Chair of BLF Scientific Committee |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Impact | Chair of the BLF helps sets the research priorities for lung research in the UK |
| Description | Committee for the Medical Effects of Air Pollutants |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Impact | Policy relating to Air Quality and advice to the public. I was Founder Chair for 15 years and then Chaired Defra's EPAQS that became subsumed into COMEAP as its Standards Quality Subgroup. |
| URL | https://www.gov.uk/government/groups/committee-on-the-medical-effects-of-air-pollutants-comeap |
| Description | European Respiratory Society (ERS) Chair of Science Council and Member of ERS Executive |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | My role in the ERS is to oversee the Fellowship programme, Seminars, Lung Science Conference, Programme Committee of the Annual Congress, Clinical Research Collaboratives and Task Forces for Guidelines. |
| URL | http://www.ersnet.org/about-us/leadership/science-council.html |
| Description | Horizon 2020 Science Panel for Health (Member from UK) |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| URL | https://ec.europa.eu/programmes/horizon2020/en/h2020-section/scientific-panel-health-sph |
| Guideline Title | Asthma Management Guidelines 2008 |
| Description | Inflammation as the basis of asthma |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Better treatment of asthma. |
| URL | http://www.ginasthma.org/ |
| Guideline Title | Global Innitiative for Asthma |
| Description | Inflammation as underlying the need for controller drugs in asthma management |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Better asthma diagnosis and treatment. |
| URL | http://www.ginasthma.org/ |
| Description | Kennedy Trust for rheumatological disease research; Trustee and member of its Scientific Straegy Board |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | This research charity is focused in large part in supporting links to the new Kennedy Institute in Oxford. More recently we have explored outreach to support research nationally and at Birmingham and Newcastle. |
| URL | http://www.kennedytrust.org/ |
| Description | MRC Strategy Board and Translational Research Group. Member and Chai respectively. |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | My role is to help MRC deliver its mandate in Translational Research such as stratifed medicine, regenerative medicine and experimental medicine. I sit on MRC Stregy Board to advise on these areas. |
| URL | http://www.mrc.ac.uk/about/strategy-board-overview-groups/translational-research-group/ |
| Description | Member of the Royal Commission on Environmental Pollution |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in other policy documents |
| Impact | 10 Reports on a vast range of topics including chemicals, the urban environment, the oceons, pesticides, light pollution, biomass etc. |
| URL | http://www.thenbs.com/PublicationIndex/Documents?Pub=RCEP |
| Description | NERC Science Board - Member to help generate and oversea NERC's Research strategy |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | The main work of the NERC SB is to ensure the range and quality of its stregically directed research is of the highest standards. |
| URL | http://www.nerc.ac.uk/about/organisation/boards/science/ |
| Description | RCP/RCPH Report on Air Pollution |
| Geographic Reach | National |
| Policy Influence Type | Citation in other policy documents |
| Impact | This influential report has created new air quality initiatives in PHE, Defra and local authorities. |
| URL | https://www.rcplondon.ac.uk/projects/outputs/every-breath-we-take-lifelong-impact-air-pollution |
| Description | Science Europe (Medical Committee Member) |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a advisory committee |
| Description | Special Advisor to the HOLSC on S & T |
| Geographic Reach | National |
| Policy Influence Type | Gave evidence to a government review |
| Impact | The Report will be published in Feb 2010. |
| URL | http://www.publications.parliament.uk/pa/ld200910/ldselect/ldsctech/22/2202.htm |
| Description | The Policy Research Programme (PRP) is a national research funding programme within the Department of Health's (DH) Research and Development Directorate. I am Deputy Chair of the Grants Panel |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | The support of wide-ranging policy relavent health and medical research with clear outcomes often in difficult subject areas. |
| URL | http://www.prp-ccf.org.uk/ |
| Description | Translational Medicine Board (OSCHR) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Description | Trustee of CRUK - influencing scientific cancer discovery |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | My role is to help oversee the scientific activity of CRUK through my membership of Council, Science Strategy Committee and Audit Committee. I am also a member of the CRUK Clinical Research Centres Panel. |
| URL | http://www.cancerresearchuk.org/about-us/how-we-are-run/our-trustees |
| Description | Clinician Scientist |
| Amount | £992,869 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2009 |
| End | 11/2013 |
| Description | MRC Capacity Buildiing Studentship |
| Amount | £60,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2006 |
| End | 09/2009 |
| Description | MRC Clinician Scientist |
| Amount | £1,000,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2009 |
| End | 03/2014 |
| Description | MRC PhD Studentship |
| Amount | £60,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2007 |
| End | 09/2011 |
| Description | MRC PhD Studentship (ITTP) |
| Amount | £60,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2009 |
| End | 09/2013 |
| Description | MRC Programme Grant |
| Amount | £1,579,270 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2008 |
| End | 10/2013 |
| Description | MRC project grant |
| Amount | £675,116 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2006 |
| End | 07/2010 |
| Description | NC3R's Project Grant |
| Amount | £298,000 (GBP) |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2008 |
| End | 07/2010 |
| Description | NIHR Biomedical Research Unit (Respiratory Disease) |
| Amount | £7,000,000 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Southampton Respiratory Biomedical Research Centre |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2011 |
| End | 09/2016 |
| Description | NIHR Biomedical Research Unit (Respiratory Disease) |
| Amount | £7,000,000 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Southampton Respiratory Biomedical Research Centre |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2012 |
| End | 12/2016 |
| Description | NIHR Senior Investigator |
| Amount | £75,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2011 |
| End | 01/2016 |
| Description | Project grant |
| Amount | £499,713 (GBP) |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2011 |
| End | 06/2013 |
| Description | project grant |
| Amount | £143,553 (GBP) |
| Funding ID | 06/053 |
| Organisation | Asthma UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Asthma genetics |
| Organisation | University of Groningen |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Novel genes identified associated with asthma. |
| Collaborator Contribution | Joint studentship exchange. |
| Impact | Publications 19729670 . Also a long term relationship between Southampton and Groningen on PhD student exchanges. |
| Start Year | 2007 |
| Description | Asthma genetics |
| Organisation | University of Nottingham |
| Department | School of Molecular Medical Sciences Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Novel asthma genes; |
| Collaborator Contribution | Joint publication |
| Impact | Joint publications; 19443020 |
| Start Year | 2007 |
| Description | Asthma genetics with Profs Meyers and Bleecker, Wake Forest University |
| Organisation | Wake Forest University |
| Department | Centre for Genomics and Personalised Medicine Research |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collaboration for research and exchange of materials |
| Collaborator Contribution | Collaboration for research and exchange of materials |
| Impact | Review in press in Lancet respiratory medicine Sessions at the ERS, EAACI and ATS Congresses |
| Start Year | 2012 |
| Description | CD48 as a novel therapeutic target for asthma |
| Organisation | Hebrew University of Jerusalem |
| Department | Faculty of Medicine |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | We are exploring the role of CD48 as a key regulator of mast cell and eosinophil function in collaboration with Prof Franesco Levi-Schaffer. |
| Collaborator Contribution | They have identified the target and we are assisting in validating it in human disease. |
| Impact | We have already discussed development of blocking mAbs against CD48 with MRCT. They requested further validation which we are undertaking. |
| Start Year | 2010 |
| Description | Clinical trial of interferon beta in asthma |
| Organisation | Manchester University NHS Foundation Trust |
| Department | Respiratory Clinical Research Centre, Wythenshawe |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Identification of a lesion of beta interferon deficiency in asthmatic airways. Repacement with inhaled beta interferon in progress as a Phase 2 Clinical Trial. |
| Collaborator Contribution | Professor Woodcock and colleagues are conducting a clinical trial funded by our company Synairgen |
| Impact | Trial still in progress |
| Start Year | 2009 |
| Description | Collaboration, Anjou University Seoul Korea |
| Organisation | Ajou University |
| Department | Allergy & Clinical Immunology Department |
| Country | Korea, Republic of |
| Sector | Academic/University |
| PI Contribution | Exchange of materials and students and Mentorship |
| Collaborator Contribution | Intellectual discussions and materials |
| Impact | Joint publications |
| Start Year | 2008 |
| Description | Genetic control of asthma |
| Organisation | University of Cincinnati |
| Department | Respiratory Research Cincinnati |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Generated conditional gene manipulated mice (via an MRC Clinician Scientist award) |
| Collaborator Contribution | Helped us develop tradgenic mice for ADAM33 and epithelial research in asthma |
| Impact | Publications. |
| Start Year | 2010 |
| Description | Genetics of asthma |
| Organisation | Wake Forest University |
| Department | Department of Genetics |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collaboration relating to data and sample exchange |
| Collaborator Contribution | Intellectual, exchange visits and exchange of clinical data and samples for genetic studies.Exchange of samples and clinical data |
| Impact | Participation in a grant proposal in MRC Strastified Medicine Innitiative. |
| Start Year | 2011 |
| Description | Genetics of asthma |
| Organisation | Wake Forest University |
| Department | Department of Genetics |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collaboration relating to data and sample exchange |
| Collaborator Contribution | Intellectual, exchange visits and exchange of clinical data and samples for genetic studies.Exchange of samples and clinical data |
| Impact | Participation in a grant proposal in MRC Strastified Medicine Innitiative. |
| Start Year | 2011 |
| Description | Meigunyah Destinguished Visiting Fellowship |
| Organisation | University of Melbourne |
| Department | Department of Pharmacology |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Although the innitial collaboration with Professors Alastair Stewart and Garry Anderson, began 1n 2010, the award to me of this prestigeous Fellowship is enabling collaborative reserch and staff exchange with the University of Melbourne |
| Collaborator Contribution | We have been working together to launch a nw Lung Centre in Melbourne, This will be anounced at the Public Lecture which is part of this Fellowship. |
| Impact | None at present but anticipated |
| Start Year | 2012 |
| Description | Norwich Medical School |
| Organisation | University of East Anglia |
| Department | School of Medicine UEA |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the Med Sch Scientific Advisory Board (Chair Sir Nicholas Wright) |
| Collaborator Contribution | One way at present |
| Impact | Reports to Medical School |
| Start Year | 2012 |
| Description | Translational medicine at Manchester |
| Organisation | University of Manchester |
| Department | Manchester Academic Health Science Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Helped Manchester University shape and prioritise its translational medicine programmes. I was awarded a 3 year Visiting Professorship to do this |
| Collaborator Contribution | It has been largely my helping them. |
| Impact | Appointment of a new Chair in Translational Medicine |
| Start Year | 2012 |
| Title | ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES |
| Description | Interferon treatment of asthma and COPD |
| IP Reference | JP2007528890 |
| Protection | Patent application published |
| Year Protection Granted | 2007 |
| Licensed | Yes |
| Impact | Synairgen conducting Phase 2 Clinical Trials. Now oulicensed to AZ ($230 million) see: http://www.synairgen.com/news/press-releases/2014/astrazeneca-licence-deal/ |
| Title | ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES |
| Description | The present invention provides the use of IFN-beta, an agent that increases the expression of IFN-beta, or a polynucleotide which is capable of expressing IFN-beta or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. |
| IP Reference | WO2005087253 |
| Protection | Patent granted |
| Year Protection Granted | 2005 |
| Licensed | Yes |
| Impact | Clinical Trial (Phase 2) in progress tpo be completed Dec 2011 |
| Title | Anti-virus therapy for respiratory diseases |
| Description | Inhaled interferon treatment in respiratory disese caused by viruses |
| IP Reference | US20070134763 |
| Protection | Patent application published |
| Year Protection Granted | 2007 |
| Licensed | Yes |
| Impact | Clinical trials in progress with Synairgen |
| Title | Anti-virus therapy for respiratory diseases |
| Description | The present invention provides the use of IFN-beta, an agent that increases the expression of IFN-beta, or a polynucleotide which is capable of expressing IFN-beta or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-lambda for the same purpose. |
| IP Reference | US2007134763 |
| Protection | Patent granted |
| Year Protection Granted | 2007 |
| Licensed | Yes |
| Impact | Clinical trials in progress with Synairgen. |
| Title | INTERFERON-beta FOR ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASE |
| Description | PROBLEM TO BE SOLVED: To provide a medicine for treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary diseases. ;SOLUTION: An agent (a) that increases endogenous interferon-ß (IFN-ß) expression in the lung or a polynucleotide (b) that can express the agent (a) is used in the production of the medicine for treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary diseases (COPD), wherein the treatment is performed by airway delivery of the medicine. ;COPYRIGHT: (C)2011,JPO&INPIT |
| IP Reference | JP2011144201 |
| Protection | Patent application published |
| Year Protection Granted | 2011 |
| Licensed | Yes |
| Impact | Clinical trials in progress with Synairgen. |
| Title | Inhaled Interferon Beta for treating COVID 19; rial of inhaled anti-viral (SNG001) for SARS-CoV-2 (COVID-19) infection |
| Description | The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2021 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | None yet; still in clinical trial |
| URL | https://pharmaphorum.com/news/synairgen-starts-dosing-inhaled-covid-19-drug-in-phase-3-trial/ |
| Title | Interferon beta |
| Description | We founded Synairgen in 2005 with a subsequent launch on AIM. Our recent (2009) fund raising will provide resource to take us through Phase 2 for IFN in asthma, Copd exacerbations and influenzaandemics. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2006 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | A new therapy of inhalede IFN for asthma, COPD and influenza independant of drug resistence. |
| URL | https://www.synairgen.com/ |
| Title | Interferon beta in COPD Exacerbations: Phas II Clinical Trial |
| Description | A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2020 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Product still being assessed |
| URL | http://synairgen.web01.hosting.bdci.co.uk/umbraco/Surface/Download/GetFile?cid=ed83495c-e8ed-43c7-8f... |
| Company Name | Synairgen |
| Description | New treatments for asthma and COPD. http://www.synairgen.com/ |
| Year Established | 2004 |
| Impact | In haled Interferon beta trials for asthma, COPD and influenza. Biomarkers and biobank |
| Website | http://www.synairgen.com |
| Company Name | Synairgen |
| Description | Synairgen is a drug discovery and development company specialising in respiratory diseases with a focus on asthma and chronic obstructive pulmonary disease (COPD). It was spun out of the University of Southampton in 2003. A small lean and highly focused company to develop new respiratory drugs. Most of our effort is now focused on an inhaled formulation of IFN beta for treating severe virus-induced exacerbations of asthma and COPD as well as hospital-based influenza admissions.; http://www.synairgen.com/ |
| Impact | Successful preclinical and Phase 1 development of inhaled interferon beta for treatment of virus-induced asthma exacerbations. We are entering phase 2a for asthma and COPD indications after a successful 2nd fund raising round in early 2009. |
| Website | http://www.synairgen.com |
| Description | Charity Newsletter |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Uptake of more individuals into Clinical Trials Local input into press |
| Year(s) Of Engagement Activity | 2006,2007,2008,2009,2010,2011,2012,2013,2014,2015,2016,2017,2018,2019 |
| Description | EU Parliament : Brussels Declaration on Asthma. |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Wporked with an MEP to bring together patient organisations, professionals and the industry to agree new and needed directions for asthma management. Influennce over Management Guidelines. |
| Year(s) Of Engagement Activity | 2007 |
| Description | Established AAIR Charity (Founder) |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Multiple interactions at public lectures and schools; charitable fund raising activities also. Active fund raising by the public for the Charity and to raise awareness of asthma |
| Year(s) Of Engagement Activity | 2007,2008,2009 |
| Description | Established All Party Parliamentary Group on Allergy |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | NASG has founded this Group to interact with parliamentarians over improved allergy provision Allergy now recognised as a public health problem. |
| Year(s) Of Engagement Activity | 2007,2008,2009,2012 |
| Description | Established United Kingdom Respiratory Research Collaborative. |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | A multiproffesional interaction to promote greater lung-related research in the UK (Founding Chair) Since 2005 3-fold increase in success rate of lung research funding including MRC. |
| Year(s) Of Engagement Activity | 2006,2007,2008,2009,2012,2013,2014,2015 |
| Description | Founded the National Allergy Strategy Group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Created a unique Group for proffessionals (BSACI) and charities (Allergy UK, the Allergy Alliance, Anaphylaxis Campaign) to join forces to promote better allergy provisionin the UK House of Lords S & T Committee Review of Allergy Services and formation of a Commissioning Group. |
| Year(s) Of Engagement Activity | 2006,2007,2008,2009 |
| Description | Keynote lecture for Action for ME |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Health professionals |
| Results and Impact | I was invited by AfME to give the opening lecture for their AGM (about 150 in audience) Many follow-up encouraging emails |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.actionforme.org.uk |
| Description | Launch of major air pollution and health Report from RCP/RCPH |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | 18 month Working Group Report by RCs to produce an integrated health report on the lifecourse effects of chronic air pollution exposure. We wish to move towards a new Clean Air Act. |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://www.rcplondon.ac.uk/projects/outputs/every-breath-we-take-lifelong-impact-air-pollution |
| Description | MP visits to the laboratory |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Our local MPs have visited our laboratories on a number of occasions. Representation of views in Parliament. |
| Year(s) Of Engagement Activity | 2007,2008 |
| Description | Medicine and Me Conferences at RSM |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | I have participated actively in 3 RSM Patient Medicine and Me Conferences (Asthma, Allergy, CFS) Greater awareness of the diseases and their management. |
| Year(s) Of Engagement Activity | 2007,2008,2009,2012 |
| Description | Multiple interactions with the local and national press |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | I am frequently contacted by the press, radio and TV for interviews relating to asthma and allergy. Publication in the lay press and attraction of funding to our charity AAIR |
| Year(s) Of Engagement Activity | 2006,2007,2008,2009,2010,2012,2013,2014,2015,2016,2017,2018,2019,2020 |
| Description | President of the British Thoracic Society |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | As President of the BTS I promulgated research findings and promoted lung research to many different professionals. Greater awareness of lung diseases |
| Year(s) Of Engagement Activity | 2006,2008 |
| Description | Talk to Dorset ME Association |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | 60 members of the opublic and patients/carers with CFS/ME Sept 2013 inWimbourne Minster Patien volunteering for trials. email messages concerning the help they received during the presentation. |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.dorsetmesupport.org.uk/ |
| Description | Wade Lecture |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | A public lecture about stratified medicine given to the School of Medicine as their Annual lecture Many follow up emails indicating genuine engagement |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://southampton.ac.uk/medicine |